Rosemont Pharmaceuticals keeps the medicine flowing. The drugmaker specializes in generic oral liquid formulations of drugs for patients who have difficulty swallowing pills and capsules, oftentimes elderly patients or young children. It makes more than 90 licensed products under its own brand -- including antibiotics, cardiovascular treatments, analgesics, and corticosteroids -- and distributes them primarily to hospitals, primary care centers, and pharmacies in the UK. It also makes custom liquid formulations of unlicensed drugs (called "Specials") and offers contract manufacturing services. In 2006 Close Brothers backed a management buy-out of Rosemont, which had been a subsidiary of Savient Pharmaceuticals.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

CEDRA is a contract research organization, deep in the heart of Texas. CEDRA conducts phase I-IV clinical drug trials at its facilities in Austin and San Antonio, including general pharmacodynamics (what a drug does to a live human body) and pharmacokinetics (what a live human body does to a drug). The company also performs bioequivalency studies for generic pharmaceutical makers. It has experience in testing drugs ranging from allergy medicines to pain management and Parkinson's drugs. Its research customers include pharmaceutical and biotechnology drug makers, as well as the federal government. CEDRA is a division of Worldwide Clinical Trials.

Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.

Taisho Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company. Taisho Company, along with its subsidiaries and associated companies, operates in two business segment. The Self Medication segment is engaged in the research, development, manufacture and sale of self-medication pharmaceuticals, quasi drugs and food products. This segment is also involved in the provision of insurance services, logistics services, printing services, as well as real estate leasing, management and operation services. The Prescribed Medication segment is engaged in the development, manufacture and sale of prescribed pharmaceuticals. Taisho Company has 23 subsidiaries and three associated companies. The Company acquired 97.97% stake in PT Bristol-Myers Squibb Indonesia Tbk. on October 31, 2009.

Since its founding in 2004, Anthera Pharmaceuticals' operations have consisted primarily of research and development activities. A biopharmaceutical company, Anthera Pharmaceuticals develops drug treatments for respiratory, cardiovascular, and immunological diseases. Its current candidates, which are in various phases of clinical development, include therapies for acute coronary syndrome (inflammation of heart muscle), lupus, and sickle cell disease. The company also has treatments for asthma and dermatitis in earlier stages of development. The company filed an initial public offering (IPO) in mid-2009.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

Elan Pharmaceuticals is part of the the brains behind the brawn of drugmaker Elan Corporation. The US-based subsidiary provides research and discovery services, such as the identification and development of new drug candidates, to its Irish parent, which specializes in treatments for neurological and autoimmune diseases, as well as severe pain and infectious disease medications. The company investigates possible treatments for diseases such as Alzheimer's disease, Parkinson's disease, and multiple myeloma. The subsidiary also handles marketing of Elan's approved products in the US, including multiple sclerosis/Crohn's disease treatment Tysabri and chronic pain medication Prialt.

BG Medicine wants to fill big gaps in diagnostic medicine. The biosciences researcher primarily provides drug research and development services to such top global pharmaceutical makers as Pfizer and AstraZeneca, US government agencies, and to the health care product divisions of companies like Mitsubishi. BG Medicine specializes in developing biomarkers, substances used to detect disease at a molecular level, that enable research into the causes of disease and the effectiveness of drugs used to treat them. Products in the planning and discovery stages include molecular diagnostic tests for heart disease, neurological disorders, and cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.